Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 4Thoracic 2Plasma cell 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 385Myelodysplastic Syndromes 153Leukemia, Myelomonocytic, Chronic 76Leukemia 65Recurrence 27Hematologic Neoplasms 20Myeloproliferative Disorders 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Anemia, Refractory, with Excess of Blasts 14Neoplasms 13Neoplasm, Residual 11Multiple Myeloma 11Leukemia, Monocytic, Acute 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Biphenotypic, Acute 11Lymphoma, Non-Hodgkin 10Leukemia, Myelomonocytic, Acute 10Primary Myelofibrosis 9Leukemia, Erythroblastic, Acute 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic-Myeloproliferative Diseases 8Lymphoma 8Leukemia, Myeloid 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia, Megakaryoblastic, Acute 8Congenital Abnormalities 8Leukemia, Myelomonocytic, Juvenile 5Hodgkin Disease 5GATA2 Deficiency 5Lymphoma, Large B-Cell, Diffuse 4

Interventions

Paclitaxel 2Azacitidine 2temsirolimus 1sargramostim 1ruxolitinib 1rucaparib 1pembrolizumab 1fludarabine 1ceritinib 1cc-486 1carboxyamido-triazole 1bemcentinib 1acalabrutinib 1abiraterone 1Uncertainty 1Thalidomide 1Temozolomide 1Sorafenib 1Quality of Life 1Psychosocial Intervention 1Patient Reported Outcome Measures 1Oxaliplatin 1O(6)-benzylguanine 1Molecular Diagnostic Techniques 1Leucovorin 1Lenalidomide 1Interleukin-2 1Interleukin-15 1Injections 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × Azacitidine × Other hematologic neoplasm × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡